Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer

Jennifer L. Osborn, Gary G. Schwartz, David C. Smith, Robert Bahnson, Roger Day, Donald L. Trump

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

Epidemiologic and experimental data support a role for 1,25-dihydroxyvitamin D3 in the growth regulation of prostate cancer. We conducted a phase II clinical trial evaluating calcitriol (1,25(OH)2D3) in patients with hormone refractory prostate cancer. We enrolled 14 patients in this study. 1,25(OH)2D3 was initiated at a daily oral dose of 0.5 μg and escalated to 1.5 μg daily. No objective responses were observed. However, in two patients decreases of 25% and 45% in prostate specific antigen levels were seen. Hypercalcemia was the predominant toxicity. We conclude that 1,25(OH)2D3 given in this manner is inactive in advanced prostate cancer. Dose escalation of oral 1,25(OH)2D3 is limited by hypercalcemia.

Original languageEnglish (US)
Pages (from-to)195-198
Number of pages4
JournalUrologic Oncology: Seminars and Original Investigations
Volume1
Issue number5
DOIs
StatePublished - Jan 1 1995

Fingerprint

Calcitriol
Prostatic Neoplasms
Hypercalcemia
Hormones
Phase II Clinical Trials
Prostate-Specific Antigen
Growth
1,25-dihydroxyvitamin D

Keywords

  • 1
  • 25(OH)D
  • Prostate cancer
  • Vitamin D
  • calcitriol
  • therapeutics

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. / Osborn, Jennifer L.; Schwartz, Gary G.; Smith, David C.; Bahnson, Robert; Day, Roger; Trump, Donald L.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 1, No. 5, 01.01.1995, p. 195-198.

Research output: Contribution to journalArticle

Osborn, Jennifer L. ; Schwartz, Gary G. ; Smith, David C. ; Bahnson, Robert ; Day, Roger ; Trump, Donald L. / Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. In: Urologic Oncology: Seminars and Original Investigations. 1995 ; Vol. 1, No. 5. pp. 195-198.
@article{048721bfb23244df8ecf23d5ad3e4df4,
title = "Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer",
abstract = "Epidemiologic and experimental data support a role for 1,25-dihydroxyvitamin D3 in the growth regulation of prostate cancer. We conducted a phase II clinical trial evaluating calcitriol (1,25(OH)2D3) in patients with hormone refractory prostate cancer. We enrolled 14 patients in this study. 1,25(OH)2D3 was initiated at a daily oral dose of 0.5 μg and escalated to 1.5 μg daily. No objective responses were observed. However, in two patients decreases of 25{\%} and 45{\%} in prostate specific antigen levels were seen. Hypercalcemia was the predominant toxicity. We conclude that 1,25(OH)2D3 given in this manner is inactive in advanced prostate cancer. Dose escalation of oral 1,25(OH)2D3 is limited by hypercalcemia.",
keywords = "1, 25(OH)D, Prostate cancer, Vitamin D, calcitriol, therapeutics",
author = "Osborn, {Jennifer L.} and Schwartz, {Gary G.} and Smith, {David C.} and Robert Bahnson and Roger Day and Trump, {Donald L.}",
year = "1995",
month = "1",
day = "1",
doi = "10.1016/1078-1439(95)00061-5",
language = "English (US)",
volume = "1",
pages = "195--198",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer

AU - Osborn, Jennifer L.

AU - Schwartz, Gary G.

AU - Smith, David C.

AU - Bahnson, Robert

AU - Day, Roger

AU - Trump, Donald L.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Epidemiologic and experimental data support a role for 1,25-dihydroxyvitamin D3 in the growth regulation of prostate cancer. We conducted a phase II clinical trial evaluating calcitriol (1,25(OH)2D3) in patients with hormone refractory prostate cancer. We enrolled 14 patients in this study. 1,25(OH)2D3 was initiated at a daily oral dose of 0.5 μg and escalated to 1.5 μg daily. No objective responses were observed. However, in two patients decreases of 25% and 45% in prostate specific antigen levels were seen. Hypercalcemia was the predominant toxicity. We conclude that 1,25(OH)2D3 given in this manner is inactive in advanced prostate cancer. Dose escalation of oral 1,25(OH)2D3 is limited by hypercalcemia.

AB - Epidemiologic and experimental data support a role for 1,25-dihydroxyvitamin D3 in the growth regulation of prostate cancer. We conducted a phase II clinical trial evaluating calcitriol (1,25(OH)2D3) in patients with hormone refractory prostate cancer. We enrolled 14 patients in this study. 1,25(OH)2D3 was initiated at a daily oral dose of 0.5 μg and escalated to 1.5 μg daily. No objective responses were observed. However, in two patients decreases of 25% and 45% in prostate specific antigen levels were seen. Hypercalcemia was the predominant toxicity. We conclude that 1,25(OH)2D3 given in this manner is inactive in advanced prostate cancer. Dose escalation of oral 1,25(OH)2D3 is limited by hypercalcemia.

KW - 1

KW - 25(OH)D

KW - Prostate cancer

KW - Vitamin D

KW - calcitriol

KW - therapeutics

UR - http://www.scopus.com/inward/record.url?scp=0001013226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0001013226&partnerID=8YFLogxK

U2 - 10.1016/1078-1439(95)00061-5

DO - 10.1016/1078-1439(95)00061-5

M3 - Article

AN - SCOPUS:0001013226

VL - 1

SP - 195

EP - 198

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 5

ER -